Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors

Executive Summary

Tesaro Inc.'s stock price more than doubled on June 29 after the company reported positive progression-free survival (PFS) data for its PARP inhibitor niraparib in the Phase III NOVA clinical trial, which tripled PFS for some women with ovarian cancer compared with placebo – a result that lifted the values of competing firms.

Advertisement

Related Content

Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza
Clovis Transitions To Commercial Stage On Rubraca Approval
Keeping Track: Opdivo Dosing Simplified; Yosprala, Cuvitru Approved; Telotristat Review Lengthened
Medivation Sees Potential For Combinations Out Of Opdivo Failure
Medivation Hopes Details On Talazoparib Will Inspire Heightened M&A Bidding
Medivation Gets Hostile After Sanofi's "Misleading" Maneuvers
Clovis Pulls Plug On Rociletinib On Expected FDA Rejection
FDA defies advisers; OK's AZ's ovarian cancer drug Lynparza
ASCO: Spotlight shines on PARP inhibitors, but no star emerges

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel